LOS ANGELES, March 12, 2026 (GLOBE NEWSWIRE) -- ServiceTitan (NASDAQ: TTAN), the software platform that powers the trades, today announced financial results for the fiscal fourth quarter and full fiscal year ended January 31, 2026. “Our vision and mission from the beginning have been simple: to inflect our customers' revenue and margins by automating their operations” said Ara Mahdessian, Co-Founder and CEO. “I am deeply proud to surpass a $1B annualized revenue run rate and to see our vision unfold faster than we ever could have imagined.” “In FY27, we're planning to continue executing on our multi-year growth opportunities, to bring the Agentic Operating System for the trades to life, and to make a step function change in the velocity at which we execute,” said Vahe Kuzoyan, Co-Founder and President, “Behind compelling results from our pilot, we are doubling the capacity of Max this quarter, with plans to further expand over the course of the year.” Fiscal Fourth Quarter and Full Fiscal Year 2026 Financial and Operational Highlights: Fiscal Fourth Quarter 2026 Fiscal Fourth Quarter 2025 Full Fiscal Year 2026 Full Fiscal Year 2025 (in millions, except percentages, GTV and active customers) Gross transaction volume (“GTV”) (in billions)(1) $19.8 $17.0 $82.1 $68.5 YOY GTV growth 16% 26% 20% 23% Total revenue $254.0 $209.3 $961.0 $771.9 YOY revenue growth 21% 29% 24% 26% Platform revenue $245.1 $200.1 $925.4 $739.5 YOY platform revenue growth 23% 30% 25% 27% GAAP loss from operations ($42.7 ) ($99.9 ) ($169.2 ) ($230.0 ) Non-GAAP income from operations(2) $27.1 $6.9 $94.1 $25.2 Non-GAAP operating margin(2) 10.7% 3.3% 9.8% 3.3% GAAP net cash provided by operating activities $40.6 $15.4 $110.1 $37.1 Non-GAAP free cash flow(2) $35.4 $10.8 $85.1 $15.5 Net dollar retention > 110% > 110% Total active customers ~10,800 ~9,500 Gross dollar retention > 95% > 95% _________________________ (1) Gross Transaction Volume (“GTV”) represents the sum of total dollars invoiced by our c...

- FY’25 Total Revenue Up 16% YoY to $469.5 Million - - FY’25 Operating Cash Flow Up 23% YoY to $81.1 Million - - FY ‘25 Net Income Increased to $41.9 Million, with Adj. EBITDA up 3x to $56.0 Million - - MISO Accepted ERAS Application for 515MW Gas Generation Expansion - TERRE HAUTE, Ind., March 12, 2026 (GLOBE NEWSWIRE) -- Hallador Energy Company (Nasdaq: HNRG) (“Hallador” or the “Company”) today reported its financial and operating results for the fourth quarter and full year ended December 31, 2025. “Hallador delivered strong 2025 financial results with double-digit growth across revenue and operating cash flow, and a 3x improvement in Adjusted EBITDA,” said Brent Bilsland, President and Chief Executive Officer. “We have recently received additional competitive offers to acquire our accredited capacity for over a decade in length. We are excited by what we are seeing in the market as Hallador is in a strong, long capacity position that continues to get better with time. We hope to be making more announcements on this topic in the near future.” “In December, we were fortunate to be awarded one of the 50 ERAS application slots, and our application was accepted with our ~$14 million deposit advancing our proposed 515 MW natural gas generator project at the Merom site. With our application now accepted into the ERAS process, we have cleared another important milestone in that review. If successfully executed, the ERAS expansion would represent a nearly 50% increase in power generation capabilities for the company. We believe Merom’s existing infrastructure and interconnection position us competitively in a market that continues to show growing demand for accredited capacity, and we are advancing commercial discussions, equipment planning and financing initiatives as we target completion by the third quarter of 2029.” Bilsland added, “Subsequent to year-end, we were excited to add Barbara Sugg, former CEO of Southwest Power Pool, Inc. (SPP) and Daniel Hudson, founder o...

CERRITOS, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI” or the “Company”), one of the largest value-based community oncology groups in the United States, today reported financial results for its fourth quarter and year ended December 31, 2025. Recent Operational Highlights Cash flow from operations in Q4 2025 was approximately $3.2 million, due to disciplined working capital management and overall increase in gross profit margin Continued expansion of our capitated footprint, initiating 9 new capitated contracts during 2025 in CA, FL, and NV, representing approximately 260,000 additional lives under management Further ramped our capitation partnership with Elevance in Florida during the fourth quarter and remains on track to continue expansion across the state in 2026 which would more than double the current partnership Initiated capitation agreements with Humana and CarePlus in Florida during the fourth quarter, further expanding payor partnerships and representing approximately 22,000 additional MA lives in South Florida Fourth Quarter 2025 Financial Highlights All comparisons are to the quarter ended December 31, 2024 unless otherwise noted Consolidated revenue of $142.0 million, increased 41.6% Gross profit of $22.7 million, an increase of 55.2% Net loss of $7.5 million compared to $13.2 million Basic and diluted loss per share of $(0.06) compared to $(0.14) Adjusted EBITDA of $147 thousand compared to $(7.8) million Cash and cash equivalents of $33.6 million as of December 31, 2025 Year Ended 2025 Financial Highlights All comparisons are to the year ended December 31, 2024 unless otherwise noted Consolidated revenue of $502.7 million, increased 27.8% Gross profit of $76.4 million, an increase of 41.6% Net loss of $60.6 million compared to $64.7 million Basic and diluted loss per share of $(0.54) and $(0.71) Adjusted EBITDA of $(12.4) million compared to $(35.7) million Cash and cash equivalents of $33.6 million as ...

SALT LAKE CITY, March 12, 2026 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. (“Health Catalyst,” Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today reported financial results for the quarter and year ended December 31, 2025. “We closed 2025 with solid performance across our business, including total revenue of $311.1 million and Adjusted EBITDA of $41.4 million,” said Ben Albert, CEO of Health Catalyst “In 2026, we are focused on the future and on positioning Health Catalyst for long‑term success. As I continue to assess the business, I see both meaningful opportunities and clear areas where we must improve. I am confident in the strengths that continue to differentiate this company. Our mission, our people, and our core capabilities, grounded in thousands of improvement projects and billions of dollars in validated impact, provide a solid foundation for delivering meaningful value to our clients and shareholders. My priority is to build on these strengths, address our challenges with clarity and discipline, and move the company forward with a renewed sense of focus and execution.” Financial Highlights for the Three and Twelve Months Ended December 31, 2025 Key Financial Measures Three Months Ended December 31, Year over Year Change Twelve Months Ended December 31, Year over Year Change 2025 2024 2025 2024 GAAP Financial Measures: (in thousands, except percentages) (in thousands, except percentages) Total revenue $ 74,679 $ 79,606 (6 )% $ 311,136 $ 306,584 1 % Gross profit $ 31,385 $ 28,618 10 % $ 120,356 $ 114,503 5 % Gross margin 42.0 % 35.9 % 38.7 % 37.3 % Net loss $ (91,025 ) $ (20,673 ) (340 )% $ (177,974 ) $ (69,502 ) (156 )% Non-GAAP Financial Measures:(1) Adjusted Gross Profit $ 39,962 $ 37,121 8 % $ 159,107 $ 149,533 6 % Adjusted Gross Margin 53.5 % 46.6 % 51.1 % 48.8 % Adjusted EBITDA $ 13,786 $ 7,911 74 % $ 41,408 $ 26,105 59 % ________________________ (1) These measures are not calculated in acc...

Record Quarterly Collections Grow 41% to $245.3 Million and Record Deployments Grow 6% to $380.5 Million Fourth Quarter Pre-tax Income up 50% to $44.1 Million with Net Income of $37.7 Million and EPS of $0.58 Fourth Quarter Adjusted Pre-tax Income up 15% to $51.1 Million with Adjusted Net Income of $44.7 Million and Adjusted EPS of $0.69 Board of Directors Declares Quarterly Cash Dividend of $0.24 per Share MINNEAPOLIS, March 12, 2026 (GLOBE NEWSWIRE) -- Jefferson Capital, Inc. (“Jefferson Capital”), a leading analytically driven purchaser and manager of charged-off, insolvency and active consumer accounts, today announced its fourth quarter and full year 2025 financial results. “We finished the year with record collections, deployments and estimated remaining collections, or ERC - exceptional performance across all key operating aspects of the business,” said David Burton, Chairman and Chief Executive Officer. “We feel confident in our momentum going into 2026 as we continue to focus on driving profitable growth and maximizing shareholder value.” “The Bluestem portfolio purchase closed on December 4th, and we believe the transaction solidifies our leadership position as a strategic acquirer of a wide spectrum of dislocated consumer credit assets. We are pleased with portfolio performance to date and expect Bluestem to be a meaningful contributor to our financial results in 2026.” “Following quarter end, we executed a follow-on equity offering, which reduced the ownership of J.C. Flowers to 53% and substantially increased our float and liquidity. The company repurchased $58.9 million of stock to support that transaction.” Fourth Quarter 2025 Highlights (vs. Fourth Quarter 2024) Record collections grew 41% to $245.3 million Record deployments up 6% to $380.5 million Record ERC rose 23% reaching $3.4 billion Record revenue up 30% to $154.8 million Sector-leading Cash Efficiency Ratio of 71.0% Leverage ratio* improved to 1.82x as compared to 2.72x Pre-tax Income up 50%...

DENVER, March 12, 2026 (GLOBE NEWSWIRE) -- EverCommerce Inc. ("EverCommerce" or the "Company") (NASDAQ: EVCM), a leading AI-powered platform helping service SMBs run smarter and grow faster, announced today financial results for the quarter and year ended December 31, 2025. Fourth Quarter 2025 Financial Highlights Revenue from continuing operations of $151.2 million, an increase of 5.2% compared to $143.7 million for the quarter ended December 31, 2024. Pro forma revenue increased approximately 4.6% compared to $144.5 million for the quarter ended December 31, 2024. from continuing operations of $151.2 million, an increase of 5.2% compared to $143.7 million for the quarter ended December 31, 2024. increased approximately 4.6% compared to $144.5 million for the quarter ended December 31, 2024. Subscription and transaction fee revenue from continuing operations of $144.1 million, an increase of 4.7% compared to $137.6 million for the quarter ended December 31, 2024. Pro forma subscription and transaction fee revenue increased approximately 4.1% compared to $138.5 million for the quarter ended December 31, 2024. from continuing operations of $144.1 million, an increase of 4.7% compared to $137.6 million for the quarter ended December 31, 2024. increased approximately 4.1% compared to $138.5 million for the quarter ended December 31, 2024. Net income from continuing operations was $5.7 million, or $0.03 per basic and diluted share, for the quarter ended December 31, 2025, compared to $12.5 million, or $0.06 per basic and diluted share, for the quarter ended December 31, 2024. from continuing operations was $5.7 million, or $0.03 per basic and diluted share, for the quarter ended December 31, 2025, compared to $12.5 million, or $0.06 per basic and diluted share, for the quarter ended December 31, 2024. Adjusted EBITDA was $44.2 million for the quarter ended December 31, 2025, compared to $44.1 million for the quarter ended December 31, 2024. “EverCommerce’s fourth quarte...

Cash Flow from Operations : Cash flow from operations was $93.0 million, compared to $83.6 million in the fourth quarter of fiscal 2025. Free cash flow was $70.1 million, compared to $75.2 million in the fourth quarter of fiscal 2025. Net Loss per Share : GAAP net loss per share was $(0.43), compared to $(0.61) in the fourth quarter of fiscal 2025. GAAP net loss includes $84.9 million in stock-based compensation expense, compared to $86.0 million in the fourth quarter of fiscal 2025. Non-GAAP net income per share, diluted, was $0.04, compared to non-GAAP net loss per share, diluted, of $(0.18) in the fourth quarter of fiscal 2025. Subscription ARR Contribution Margin : Subscription ARR contribution margin was 11.6% compared to 2.1% in the fourth quarter of fiscal 2025, reflecting the strong net new subscription ARR in the quarter and an improvement in operating leverage in the business. Gross Margin : GAAP gross margin was 81.5%, compared to 77.4% in the fourth quarter of fiscal 2025. This includes $4.4 million in stock-based compensation expense, compared to $5.1 million in the fourth quarter of fiscal 2025. Non-GAAP gross margin was 83.7%, compared to 79.7% in the fourth quarter of fiscal 2025. Revenue : Subscription revenue was $364.9 million, a 50% increase compared to $243.7 million in the fourth quarter of fiscal 2025. Total revenue was $377.7 million, a 46% increase compared to $258.1 million in the fourth quarter of fiscal 2025. This includes $18 million in revenue from material rights. Revenue excluding material rights increased 43% year-over-year in the fourth quarter of fiscal 2026. Commenting on the company’s financial results, Kiran Choudary, Rubrik’s Chief Financial Officer, added, "We concluded fiscal 2026 with an exceptionally strong performance, highlighted by a record $115 million in net new subscription ARR and significant free cash flow. We look forward to continuing to execute in our large and growing market opportunity in fiscal 2027 and beyond...

INO-3107 – Recurrent Respiratory Papillomatosis (RRP) In December 2025, the FDA accepted INOVIO's BLA for INO-3107 for review under the accelerated approval program as a potential treatment for adults with RRP. As part of the submission, INOVIO requested a priority review, which is typically 6 months. Instead, the FDA granted a standard 10-month review with a PDUFA target date set for October 30, 2026. "With our first BLA now under review by the FDA, we are focused on delivering INO-3107 to RRP patients who are desperate for treatment options that reduce reliance on surgery to control this rare and devastating disease," said Dr. Jacqueline Shea, INOVIO's President and Chief Executive Officer. "Our top priority is advancing INO-3107, and to do so, optimizing and extending our financial resources towards our target PDUFA date of October 30, 2026. We are excited about the opportunities ahead as we prepare to become a commercial-stage company and work to leverage the power of partnerships to advance other promising candidates in our pipeline. I look forward to providing more updates on our progress with these efforts in the coming months." PLYMOUTH MEETING, Pa., March 12, 2026 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced its financial results for the fourth quarter and full year ended December 31, 2025 and provided an update on recent company developments. Announced clinical trial collaboration and supply agreement with Akeso Inc. to evaluate INO-5412 in combination with cadonilimab for the potential treatment of glioblastoma (GBM) in a Dana-Farber Cancer Institute-sponsored trial Biologics License Application (BLA) for INO-3107 accepted for review under the Accelerated Approval Program as a potential treatment for adults with Recurrent Respiratory Papillomatosis (RRP) by the U.S. Food and D...

CEO Transition: SenesTech's Board has initiated a formal search for a new CEO following Joel Fruendt's retirement, and appointed Dr. Jamie Bechtel to the newly created role of Interim Executive Chair to support leadership continuity and strategic execution during the transition period. International Expansion: Evolve secured regulatory approval in New Zealand (with the initial stocking order shipped to exclusive partner Evicom) and expanded international footprint in Belize by adding the Belize Raptor Center as an official distributor. Field Validation: Multi-month Evolve deployments in two urban study areas delivered measurable reductions in rodent activity within five months, including a 79% decline in rat activity at one site and more than a 50% decline at a second site. Amazon Direct Management: SenesTech has begun directly managing Amazon sales of Evolve Rat and Evolve Mouse, transitioning from third-party management to strengthen product presentation and customer communications, leverage performance data to optimize marketing, and retain a greater portion of e-commerce economics. While the transition created an approximately $200,000 fourth quarter revenue impact, management expects direct control to drive higher revenue and stronger margins once fully integrated. E-commerce Growth: E-commerce revenue increased 88% year-over-year from 2024 to 2025, driven by strong growth on Amazon and the Company's direct-to-consumer website, notwithstanding the loss of an estimated $200,000 in 2025 revenue as a result of the Company's transition to directly managing Amazon sales. If the Company had recognized an additional $200,000 in E-Commerce revenue for this transition, E-Commerce revenue growth would have been 130%. The balance sheet was strengthened by capital raises completed in 2025, resulting in cash and short-term investments of $8.6 million at the end of 2025. The Company believes this capital will be sufficient to provide operating runway through approximately th...

For years, Warren Buffett has continued to pile into one popular U.S.-based oil stock. That oil stock now comprises roughly 4% of Berkshire Hathaway's entire publicly traded portfolio. Now that oil prices are surging, this classic Buffett stock looks more promising than ever. That's especially the case given the company now has a strong advantage versus dozens of competing oil stocks. Occidental Petroleum produces a majority of its oil in the U.S. Occidental Petroleum (OXY +5.09%) is clearly one of Warren Buffett's favorite oil stocks right now. Before he departed as CEO of Berkshire Hathaway in December, he left the firm with a $10.9 billion position in Occidental Petroleum -- a bet that has gradually risen in value since his first purchase in 2022. When Buffett first invested in OXY stock in 2019, oil prices were around $50 to $60 per barrel.At the start of this year, oil prices remained below $60 per barrel. Expand NYSE : OXY Occidental Petroleum Today's Change ( 5.09 %) $ 2.83 Current Price $ 58.41 Key Data Points Market Cap $55B Day's Range $ 56.42 - $ 59.15 52wk Range $ 34.78 - $ 59.15 Volume 39M Avg Vol 13M Gross Margin 31.94 % Dividend Yield 1.76 % Due to recent geopolitical tensions, however, oil prices are surging once again, briefly surpassing $115 per barrel, only to settle at roughly $80 per barrel within a few days. Some analysts believe $100 per barrel pricing may be ahead yet again -- a big win for upstream oil companies that rely on rising prices to boost profits. A global domino effect is now happening due to current and expected oil production disruptions across the Middle East. China, for example, recently banned its refineries from exporting any refined fuel. The Strait of Hormuz, meanwhile -- a major chokepoint that processes 20% of global oil transportation -- faces severe uncertainty regarding its safety. While oil prices have surged in recent weeks, the stock prices for many oil producers haven't followed suit as strongly. Chevron stock, for...

Key Points Both SCHB and ITOT deliver nearly identical exposure to the U.S. stock market with matching low expenses and yields. ITOT manages more than double the assets under management of SCHB and has higher average daily volume. Sector allocations and top holdings are nearly indistinguishable, so differences may come down to trading preferences and fund size. 10 stocks we like better than iShares Trust - iShares Core S&P Total U.s. Stock Market ETF › Schwab U.S. Broad Market ETF (NYSEMKT:SCHB) and iShares Core S&P Total U.S. Stock Market ETF (NYSEMKT:ITOT) both offer ultra-low-cost, broad U.S. equity market exposure, but ITOT stands out for its larger assets under management and higher average daily volume, while SCHB remains a strong option for Schwab-centric investors. Both SCHB and ITOT aim to mirror the performance of the entire U.S. stock market, tracking thousands of companies across all sectors. This comparison looks at their costs, returns, risk, portfolio makeup, and trading characteristics to help investors decide which may better fit their needs. Snapshot (cost & size) Metric SCHB ITOT Issuer Schwab IShares Expense ratio 0.03% 0.03% 1-yr return (as of 2026-03-11) 21.7% 21.6% Dividend yield 1.1% 1.1% Beta 1.02 1.01 AUM $38.1 billion $81.5 billion Beta measures price volatility relative to the S&P 500; beta is calculated from five-year monthly returns. The 1-yr return represents total return over the trailing 12 months. Both funds are equally affordable, with each charging 0.03% in annual expenses. They also offer a 1.1% dividend yield, so cost and payout are essentially tied. Performance & risk comparison Metric SCHB ITOT Max drawdown (five years) -25.36% -25.36% Growth of $1,000 over five years $1,614 $1,606 What's inside ITOT holds 2,484 stocks spanning the entire U.S. equity market, with technology making up 33%, financial services 12%, and consumer cyclical 10%. Its largest positions—Nvidia (NASDAQ:NVDA), Apple (NASDAQ:AAPL), and Microsoft (NASDAQ:MS...

During the meeting with King Charles on Wednesday, First Nations chiefs asked the monarch to issue a Royal Proclamation that would affirm their treaties with the Crown and the rights that are afforded under them, they said.

据报道，埃隆·马斯克的AI初创公司xAI的联合创始人离职潮仍在继续。 据知情人士透露，戴子航本周早些时候已经离开xAI。他在X个人资料上的xAI徽章已经消失。 与此同时，知情人士表示，张国栋已向一些人表示，他计划在未来几天内离开公司。不过目前他的X个人资料上仍然保留着xAI徽章。 在此之前，已有多位xAI联合创始人离职，包括Toby Pohlen、Jimmy Ba、Tony Wu以及Greg Yang，这些人自今年1月以来陆续离开公司。 在戴子航和张国栋离开之后，2023年与马斯克一起创立xAI的11名创始成员中，将只剩下两人仍在公司任职，分别是Manuel Kroiss和Ross Nordeen。 张国栋直接向马斯克汇报工作，并负责公司两个关键项目：Grok Code和Grok Imagine。此前报道称，今年早些时候，在Tony Wu离开公司之前不久，张国栋在xAI获得了更大的职责范围。 周三，马斯克在Abundance Conference会议上表示：“Grok目前在编程能力方面仍然落后。” 他说：“我之所以迟到，是因为刚刚参加了一场关于编程的全体会议，讨论所有需要完成的事情，以便在编程能力上最终超越我们的竞争对手。我认为我们会做到。” 责任编辑：陈钰嘉

NVIDIA Invests $2B in Nebius: Time to Add NBIS to Your Portfolio? MarketBeat

Exchanges oppose potential US Treasury intervention in oil futures market Reuters

Allogene Therapeutics press release ( ALLO ): Q4 GAAP EPS of -$0.17 beats by $0.05 . The Company had $258.3 million in cash, cash equivalents, and investments as of December 31, 2025. Based on its cash, cash equivalents, and investments as of December 31, 2025, the Company has extended its cash runway into the first quarter of 2028. More on Allogene Therapeutics Allogene Therapeutics, Inc. (ALLO) Presents at Citi's 2026 Virtual Oncology Leadership Summit Transcript Allogene Therapeutics Q4 2025 Earnings Preview Allogene upgraded at Citizens on discounted EPS, revenue multiple Seeking Alpha’s Quant Rating on Allogene Therapeutics Historical earnings data for Allogene Therapeutics

(RTTNews) - Below are the earnings highlights for Stampede Drilling Inc. (SDI.V): Earnings: C$4.52 million in Q4 vs. C$0.68 million in the same period last year. EPS: C$0.02 in Q4 vs. C$0.00 in the same period last year. Revenue: C$21.30 million in Q4 vs. C$20.39 million in the same period last year. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

财联社3月13日讯（编辑 牛占林） 特朗普政府正考虑暂时豁免实施百年的《琼斯法案》 ，以确保能源和农产品能够在美国各港口间自由运输。白宫新闻秘书卡罗琳·莱维特当地时间周四表示，此举旨在应对因伊朗局势引发的供应中断。 "出于国防利益考虑，白宫正在考虑暂时豁免《琼斯法案》，以确保重要的能源产品和农业必需品能够自由流向美国港口，"莱维特在一份声明中表示。她补充称："这一行动尚未最终确定。" 据两位知情人士透露，关于30天豁免期的公告最早可能于周四发布，目的是应对美以针对伊朗开战以来出现的燃料价格飙升及其他供应中断问题。 汽油价格高企对特朗普及共和党同僚构成重大政治风险。他们长期以来一直宣称其能源政策将确保美国消费者能够负担得起燃料。若油价持续上涨，将削弱这一政策主张，并可能招致民主党批评，称政府未能保护家庭免受成本上涨冲击。尤其是在选民对通胀保持敏感、11月中期选举临近之际。 美国汽车协会(AAA)数据显示，周四美国全国平均汽油零售价达到每加仑3.60美元，为2024年5月以来首次；柴油价格则达到每加仑4.89美元，为2022年12月以来最高水平。 特朗普一直在研究平抑能源价格的方案，但分析师和能源专家表示，只要伊朗继续袭击霍尔木兹海峡的油轮，他的选择就十分有限。 根据《琼斯法案》规定，在美国港口之间运输的货物必须由美国建造、悬挂美国国旗且为美国公司所有的船舶承运。这一要求大幅限制了可用于国内运输的油轮数量。 专家表示，如果豁免该法规，将允许外国船只在美国港口之间运输燃料，从而有助于缓解供应中断，并可能降低能源价格。 燃料价格追踪机构GasBuddy的分析师Patrick De Haan表示，《琼斯法案》豁免对汽油价格不会产生重大影响，但可能有助于减缓西海岸和东北部等依赖进口地区的价格上涨。 这是因为从美国其他地区向这些地区运输货物将变得更加便利。但De Haan补充称，整体价格趋势仍取决于中东局势的发展。 美国最大的农业游说团体——美国农场局联合会在3月9日致信特朗普，要求豁免《琼斯法案》以改善国内运输能力，并警告称霍尔木兹海峡航运中断将导致农民化肥价格飙升。 美国过去仅在发生重大供应中断时才会零星发布《琼斯法案》豁免令。最近的豁免发生在2017年飓风哈维和飓风玛利亚之后。当时，美国国土安全部暂时允许悬挂外国国旗的船舶在美国港口间运输燃料，以缓解短缺并加快向受灾地区交付...

Conagra Brands' (CAG 4.62%) stock is relatively inexpensive right now. Trading below $20, it may look like a buy, but the company's fundamentals tell a story of challenges and significant headwinds. What's going on with Conagra, and is it worth a long-term investment? Let's dive in deeper. Expand NYSE : CAG Conagra Brands Today's Change ( -4.62 %) $ -0.79 Current Price $ 16.20 Key Data Points Market Cap $8.1B Day's Range $ 16.13 - $ 17.06 52wk Range $ 15.96 - $ 27.68 Volume 22M Avg Vol 12M Gross Margin 24.54 % Dividend Yield 8.24 % A stale brand? Conagra is a century-old consumer packaged goods (CPG) food company with several recognizable brands under its umbrella, including Marie Callender's, Healthy Choice, and Duncan Hines. The consumer staples stock has had a rough go over the past five years, declining nearly 50% in that time. Thus far this year, though, it's rebounded slightly, and is up over 8%. Conagra does pay a dividend, and its current yield is 7.36%. On the surface, this seems great, but upon deeper inspection, it raises some questions. In addition to the stock price's decline, the company's free cash flow is expected to drop substantially in 2026. For the first half of fiscal 2026, free cash flow decreased from the prior year by $313 million. The company hasn't announced a cut to dividends, but it's hard not to think this may be on the table if Conagra's finances don't improve. The CPG giant faces tremendous pressure as consumer sentiment shifts away from processed foods, leading to a decline in sales. In its second-quarter 2026 earnings, Conagra reported a 6.8% decline in net sales and an operating margin of -20.1%. There is some optimism Inflation, tariffs, and operational inefficiencies are headwinds for Conagra, but its CEO, Sean Connolly, has a more positive outlook. In the earnings release last December, Connolly stated, "While we continued to navigate a challenging consumer environment in the second quarter, I am pleased with the continued underl...

Key Points Conagra's stock declined by nearly 50% in the past five years. The company's dividend remains in tact and the current yield is 7.36%. 10 stocks we like better than Conagra Brands › Conagra Brands' (NYSE: CAG) stock is relatively inexpensive right now. Trading below $20, it may look like a buy, but the company's fundamentals tell a story of challenges and significant headwinds. What's going on with Conagra, and is it worth a long-term investment? Let's dive in deeper. A stale brand? Conagra is a century-old consumer packaged goods (CPG) food company with several recognizable brands under its umbrella, including Marie Callender's, Healthy Choice, and Duncan Hines. The consumer staples stock has had a rough go over the past five years, declining nearly 50% in that time. Thus far this year, though, it's rebounded slightly, and is up over 8%. Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue » Conagra does pay a dividend, and its current yield is 7.36%. On the surface, this seems great, but upon deeper inspection, it raises some questions. In addition to the stock price's decline, the company's free cash flow is expected to drop substantially in 2026. For the first half of fiscal 2026, free cash flow decreased from the prior year by $313 million. The company hasn't announced a cut to dividends, but it's hard not to think this may be on the table if Conagra's finances don't improve. The CPG giant faces tremendous pressure as consumer sentiment shifts away from processed foods, leading to a decline in sales. In its second-quarter 2026 earnings, Conagra reported a 6.8% decline in net sales and an operating margin of -20.1%. There is some optimism Inflation, tariffs, and operational inefficiencies are headwinds for Conagra, but its CEO, Sean Connolly, has a more positive outlook. In the earnings rel...

标普综合1500商品化学指数收涨8%。 风险提示及免责条款 市场有风险，投资需谨慎。本文不构成个人投资建议，也未考虑到个别用户特殊的投资目标、财务状况或需要。用户应考虑本文中的任何意见、观点或结论是否符合其特定状况。据此投资，责任自负。

Capricor Therapeutics, Inc. press release ( CAPR ): Q4 GAAP EPS of -$0.62 misses by $0.08 . Revenue of $0M. More on Capricor Therapeutics, Inc. Capricor Therapeutics: A High Risk/High Reward Name Capricor Therapeutics, Inc. (CAPR) Discusses HOPE-3 Phase III Trial Results and Regulatory Path for Duchenne Muscular Dystrophy Therapy Transcript Capricor Therapeutics, Inc. Q4 2025 Earnings Preview Capricor extends rally as FDA to review rejected cell therapy Seeking Alpha’s Quant Rating on Capricor Therapeutics, Inc.

The escalating conflicts across the Middle East, inflation, and murky monetary policies all dragged down U.S. stocks over the past month. However, the S&P 500 is still up 20% over the past 12 months and looks historically expensive at 29 times earnings. Therefore, investors shouldn't be surprised if the macro headwinds finally trigger a market crash and cool those valuations to more sustainable levels. If that happens, stable blue chip dividend stocks will draw in more investors as safe-haven investments. Two of those high-yield stocks are worth buying today: Energy Transfer (ET 0.93%) and Digital Realty Trust (DLR 0.33%). Energy Transfer Energy Transfer, which operates over 140,000 miles of pipeline across 44 states, is one of the largest midstream companies in America. It charges upstream extraction companies and downstream refining companies to transport natural gas, natural gas liquids (NGLs), crude oil, and other refined products through its pipelines. It also transports natural gas overseas. Expand NYSE : ET Energy Transfer Today's Change ( -0.93 %) $ -0.17 Current Price $ 18.57 Key Data Points Market Cap $65B Day's Range $ 18.56 - $ 18.96 52wk Range $ 14.60 - $ 19.30 Volume 14M Avg Vol 15M Gross Margin 12.27 % Dividend Yield 7.07 % That "toll road" business model is well-insulated from volatile commodity prices, since it only needs those resources to keep flowing to generate stable profits. It also operates as a master limited partnership (MLP) that blends a return of capital with its own income to pay tax-efficient distributions. It currently pays a high forward yield of 7.1%. In 2025, its annualized adjusted DCF of $8.2 billion easily covered its $4.6 billion in distributions. From 2025 to 2027, analysts expect Energy Transfer's earnings per unit (EPU) to grow at a 14% CAGR as it expands its infrastructure in the Permian Basin and other resource-rich regions. Its stock looks cheap at 12 times this year's EPU, so it could be a great place to park your cash a...

Key Points Energy Transfer’s “toll road” pipelines are generating stable profits. Digital Realty will profit from the secular growth of the cloud and AI markets. 10 stocks we like better than Energy Transfer › The escalating conflicts across the Middle East, inflation, and murky monetary policies all dragged down U.S. stocks over the past month. However, the S&P 500 is still up 20% over the past 12 months and looks historically expensive at 29 times earnings. Therefore, investors shouldn't be surprised if the macro headwinds finally trigger a market crash and cool those valuations to more sustainable levels. If that happens, stable blue chip dividend stocks will draw in more investors as safe-haven investments. Two of those high-yield stocks are worth buying today: Energy Transfer (NYSE: ET) and Digital Realty Trust (NYSE: DLR). Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue » Energy Transfer Energy Transfer, which operates over 140,000 miles of pipeline across 44 states, is one of the largest midstream companies in America. It charges upstream extraction companies and downstream refining companies to transport natural gas, natural gas liquids (NGLs), crude oil, and other refined products through its pipelines. It also transports natural gas overseas. That "toll road" business model is well-insulated from volatile commodity prices, since it only needs those resources to keep flowing to generate stable profits. It also operates as a master limited partnership (MLP) that blends a return of capital with its own income to pay tax-efficient distributions. It currently pays a high forward yield of 7.1%. In 2025, its annualized adjusted DCF of $8.2 billion easily covered its $4.6 billion in distributions. From 2025 to 2027, analysts expect Energy Transfer's earnings per unit (EPU) to grow at a 14% CAGR as...

Robert Way/iStock Editorial via Getty Images In the days that followed Nvidia Corporation's ( NVDA ) Q4 earnings report , investors struggled to find an explanation for the stock's decline. By all accounts, this was a blockbuster quarter for Nvidia, as I expected, with the chip giant delivering another jaw-dropping beat on top of very strong guidance. So, what gives? Most analysts suggested that investors are worried about ASICs , but I believe they're wrong. In my view, it was about a response CEO Jensen Huang gave to a question about hyperscalers' capital spending. Despite that, at current valuation levels, I argue Nvidia is a no-brainer Strong Buy, leading me to an upgrade. Numbers Were Impeccable Let's start with some context. Nvidia delivered 73% revenue growth and 98% EPS growth, vastly exceeding estimates . Nvidia Investor Presentation Against worries about higher prices from TSMC and lower profitability, gross margins returned to 75%, the highest level since calendar Q1-24. Operating margins reached an all-time high of 65%, as Nvidia continues to drive extreme operating leverage. Nvidia Investor Presentation Looking ahead, Nvidia guidance for next quarter was $78 billion in revenues, reflecting an astounding 77% growth, sustained gross margins at 75%, and another quarter of record operating margins. Simply put, results were impeccable, which is what sent analysts looking for answers after the stock fell sharply post-earnings. The Wrong Explanations Heading into earnings, I said that my biggest concern was the "ASIC Boogeyman." I wrote: It's not ideal to have your largest customers actively compete with you, but that is the reality that Nvidia is dealing with. That's what happens when your customers are the best-capitalized companies in the world, and your product has become their largest cost center. Even more so when you're generating gross margins north of 75%. However, Nvidia ended 2025 with far lower concentration than investors understand. In fact, in Q...

Nvidia: One Answer That Scared Investors (Rating Upgrade) (NASDAQ:NVDA) Seeking Alpha

Corvus Pharmaceuticals press release ( CRVS ): Q4 GAAP EPS of -$0.15 misses by $0.02 . As of December 31, 2025, Corvus had cash, cash equivalents and marketable securities of $56.8 million as compared to $52.0 million as of December 31, 2024. Cash, cash equivalents and marketable securities as of December 31, 2025 does not include approximately $189.4 million in net proceeds received in a financing completed on January 23, 2026. Based on its current plans, Corvus expects its cash to fund operations into the second quarter of 2028.

Key Points Anne Giviskos sold 31,150 shares for a transaction value of approximately ~$297K based on a weighted average price of $9.52 per share on March 3, 2026. The sale represented 29.36% of Anne Giviskos' direct holdings, reducing direct ownership to 74,940 shares. The transaction involved only direct ownership; no indirect entities were involved. Giviskos retains 74,940 shares of Class A Common Stock (direct); this activity followed a pattern of larger periodic sales as holdings capacity declined. 10 stocks we like better than Navan › Chief Accounting Officer Anne Mary Giviskos reported the sale of 31,150 shares of Navan (NASDAQ:NAVN) in an open-market transaction on March 3, 2026, according to a SEC Form 4 filing. Transaction summary Metric Value Shares sold (direct) 31,150 Transaction value ~$297K Post-transaction shares (direct) 74,940 Post-transaction value (direct ownership) ~$713K Transaction value based on SEC Form 4 weighted average purchase price ($9.52); post-transaction value based on March 3, 2026 market close ($9.52). Key questions How does this sale compare to recent insider selling patterns? This transaction was the largest of two sell trades made by Anne Mary Giviskos since October 2025, with this sale (31,150 shares) exceeding the recent median sell size of approximately 16,912 shares. This transaction was the largest of two sell trades made by Anne Mary Giviskos since October 2025, with this sale (31,150 shares) exceeding the recent median sell size of approximately 16,912 shares. What proportion of direct holdings did the transaction represent? The sale accounted for 29.36% of direct shares held prior to the transaction, a higher percentage than the median 15.91% of holdings traded per sale over the recent period. The sale accounted for 29.36% of direct shares held prior to the transaction, a higher percentage than the median 15.91% of holdings traded per sale over the recent period. Were indirect entities or trusts involved in this dispositi...

Broadcom Now Shipping World’s First 102.4 Tbps Switch in Production Volume The Globe and Mail

Starbucks ( SBUX ) shares snapped six straight sessions of gains, as the stock closed 1.4% lower at $99.99 on Thursday. The Seattle-based coffee chain gained over 4% in the preceding six sessions. Overall, the stock rose nearly 21% so far this year, compared to the 2% fall in the broader S&P 500 Index. SBUX is up nearly 4% over the past one month. The stock closed 0.7% higher on Wednesday at $101.44. Looking at Seeking Alpha's Quant Rating, SBUX has a Hold rating with a score of 3.11 out of 5. The company received A in the prospect of momentum, while it got D- in the valuation factor. Turning to the Wall Street community, 17 analysts gave SBUX a Buy and above, 17 analysts have given the stock a Hold recommendation, and four recommended Sell or lower. Seeking Alpha analysts are also cautious and see the stock as a Hold. Seeking Alpha analyst Sanjay Chandiramani said Starbucks is downgraded to a sell as returns on tangible assets and earnings yield have deteriorated, with valuation now well above historical norms. Another Seeking Alpha analyst Bela Lakos downgraded the stock from buy to hold due to deteriorating profitability and an uninspiring growth outlook. Starbucks, in January, issued its first-quarter earnings report, where it recorded its second straight quarter of positive comparable sales after a streak of seven quarters in negative territory. More on Starbucks Starbucks: What The 3-Step DuPont Model Reveals About Valuation Starbucks Just MIGHT Be Starting To See The (Asset) Lite Via China (Upgrade) Starbucks: The Growth Story Is Not Compelling Enough At The Current Valuation (Rating Downgrade) Starbucks plans Nashville office for southeast expansion CosMc's afterlife: McDonald's secret weapon to take on Starbucks and Dutch Bros